Pfizer Inc.

Sanofi

AgomAb Therapeutics N.V. American Depositary Shares

Agomab's Crohn's disease therapy is already being clinically tested

Agomab Therapeutics IPO: Pfizer and Sanofi-backed biotech starts trading

Advanced Micro Devices, Inc.

Alphabet Inc.

Novo Nordisk A/S

PayPal Holdings, Inc.

Super Micro Computer, Inc.

Merck & Co., Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: investors in search of a foothold

Eli Lilly and Company

Pharma giant's shares were down 5% in trading on February 3

Pfizer reveals data on obesity drug. Why are analysts and the market disappointed?

Novartis AG

Roche Holding AG

Amgen Inc.

Companies will get a three-year reprieve from pharmaceutical duties, provided they invest in manufacturing within the U.S.

Nine major pharma companies have made deals with Trump to lower drug prices

Other drug manufacturers may also join the list of companies for the price deal

U.S. to reach drug pricing agreements with Novartis and Roche - Bloomberg

Amazon.com, Inc.

Worthington Enterprises, Inc.

Tesla, Inc.

Lennar Corporation

RadNet, Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research

Morning in New York: foreign policy news is the market's focus

Pfizer expects revenue and profit to decline in 2026 due to weaker demand for vaccines and other products related to Covid-19. Analysts note that the company is trying to offset the pressure on its performance by cutting costs and increasing investments in research and development, but do not see any significant drivers for the stock's revaluation in the coming year.

Pfizer expects performance to fall due to lower sales of Covid vaccines. Shares fall


The White House also secured reductions in the cost of Wegovy and Pfizer's cancer drug

Novo will cut the price of Ozempic by 71% for older Americans. This will hinder revenue growth

Shares in Novo Nordisk, maker of popular obesity drugs Wegovy and Ozempic, rose 2.4% in Copenhagen trading after it pulled <a href="https://www.globenewswire.com/news-release/2025/11/08/3184043/0/en/Novo-Nordisk-will-not-increase-its-proposal-to-acquire-Metsera-Inc.html">out</a> of the race to buy U.S. healthcare startup Metsera.

Novo stock jumped after it lost a battle for a med-startup. What's the upside?

Novo Nordisk, the maker of obesity drugs Wegovy and Ozempic, and US pharma company Pfizer have improved their offers to buy US startup Metsera, which develops weight-loss drugs. The company itself still considers Novo's offer "more favorable" despite the escalating battle for the deal, the Financial Times <a href="https://www.ft.com/content/ab202cb5-ee27-4257-b2ee-431408c970c1">writes</a>.

Novo Nordisk and Pfizer raise stakes in battle for weight loss drug developer

Palantir Technologies Inc.

Uber Technologies, Inc.

Morning in New York: stocks switched to correction mode

Pharma companies squabble over a promising startup in the market for weight management products